{"id":"chondron","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site pain or swelling"},{"rate":null,"effect":"Infection at implantation site"},{"rate":null,"effect":"Graft failure or inadequate integration"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"CHONDRON involves harvesting healthy cartilage cells (chondrocytes) from a patient, expanding them in culture, and reimplanting them into areas of cartilage defect or osteoarthritis. This approach aims to restore cartilage structure and function by leveraging the patient's own cells to promote tissue regeneration and reduce joint degeneration.","oneSentence":"CHONDRON is an autologous chondrocyte-based cell therapy that regenerates cartilage tissue by implanting a patient's own expanded cartilage cells into damaged joint areas.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:05:47.097Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Cartilage defects of the knee"},{"name":"Osteoarthritis of the knee"}]},"trialDetails":[{"nctId":"NCT04236739","phase":"PHASE3","title":"Comparing Clinical Outcomes of the One-step Cartilage Transplantation in Cartilage Defects of the Knee With Conservative Treatment","status":"COMPLETED","sponsor":"R.J.H. Custers","startDate":"2019-07-23","conditions":"Cartilage Damage","enrollment":60},{"nctId":"NCT06809231","phase":"","title":"Effectiveness and Safety of Knee Cartilage Lesion Treatment Using CartiONE: 1-to-13 Year Follow-up.","status":"RECRUITING","sponsor":"Cartilage Repair Systems BV","startDate":"2024-03-01","conditions":"Knee Cartilage Lesion","enrollment":100},{"nctId":"NCT02037204","phase":"PHASE1, PHASE2","title":"IMPACT: Safety and Feasibility of a Single-stage Procedure for Focal Cartilage Lesions of the Knee.","status":"COMPLETED","sponsor":"UMC Utrecht","startDate":"2013-03","conditions":"Foreign-Body Reaction, Inflammation, Effusion (L) Knee","enrollment":35},{"nctId":"NCT02539056","phase":"PHASE4","title":"The Post-marketing Surveillance to Evaluate the Efficacy and Safety of a CHONDRON (Autologous Cultured Chondrocyte)","status":"UNKNOWN","sponsor":"Sewon Cellontech Co., Ltd.","startDate":"2012-07","conditions":"Osteoarthritis, Traumatic Arthritis","enrollment":24},{"nctId":"NCT02539069","phase":"PHASE4","title":"The Post-marketing Surveillance to Evaluate the Efficacy of CHONDRON (Autologous Cultured Chondrocyte) by Arthroscopy","status":"UNKNOWN","sponsor":"Sewon Cellontech Co., Ltd.","startDate":"2012-08","conditions":"Osteoarthritis, Traumatic Arthritis","enrollment":10},{"nctId":"NCT02537067","phase":"PHASE3","title":"Efficacy and Safety of Chondron (Autologus Chondrocyte) in Patients With Cartilage Defects in Their Ankle","status":"UNKNOWN","sponsor":"Sewon Cellontech Co., Ltd.","startDate":"2010-01","conditions":"Defect of Articular Cartilage, Degenerative Joint Disease of Ankle and/or Foot, Ankle (Ligaments); Instability, Familial","enrollment":28},{"nctId":"NCT02524509","phase":"","title":"the Safety and Efficacy Evaluation of Chondron Compared With Mircrofracture of Knee","status":"UNKNOWN","sponsor":"Sewon Cellontech Co., Ltd.","startDate":"2012-01","conditions":"Defect of Articular Cartilage, Articular Cartilage Disorder of Knee, Degeneration; Articular Cartilage, Knee","enrollment":50},{"nctId":"NCT01050816","phase":"PHASE3","title":"Effects of CHONDRON (Autologous Chondrocytes) With Ankle Cartilage Defect","status":"COMPLETED","sponsor":"Sewon Cellontech Co., Ltd.","startDate":"2006-01","conditions":"Articular Cartilage Defects of Ankle Joint","enrollment":30},{"nctId":"NCT01056900","phase":"","title":"Observation of the Result After Chondron (Autologous Chondrocytes) Treatment","status":"COMPLETED","sponsor":"Sewon Cellontech Co., Ltd.","startDate":"2008-12","conditions":"Articular Cartilage Defects of Knee","enrollment":127}],"_emaApprovals":[],"_faersSignals":[{"count":1,"reaction":"HERPES ZOSTER"},{"count":1,"reaction":"INTESTINAL OBSTRUCTION"},{"count":1,"reaction":"MUCOSAL INFLAMMATION"},{"count":1,"reaction":"PANCREATIC CARCINOMA"},{"count":1,"reaction":"POSTOPERATIVE ADHESION"},{"count":1,"reaction":"POSTOPERATIVE ILEUS"},{"count":1,"reaction":"SMALL INTESTINE CARCINOMA"},{"count":1,"reaction":"WHITE BLOOD CELL COUNT DECREASED"}],"_approvalHistory":[],"publicationCount":113,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Autologous cultured Chondrocyte"],"phase":"phase_3","status":"active","brandName":"CHONDRON","genericName":"CHONDRON","companyName":"Sewon Cellontech Co., Ltd.","companyId":"sewon-cellontech-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"CHONDRON is an autologous chondrocyte-based cell therapy that regenerates cartilage tissue by implanting a patient's own expanded cartilage cells into damaged joint areas. Used for Cartilage defects of the knee, Osteoarthritis of the knee.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}